Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IDP-023,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $22.5 million
Deal Type : Financing
Indapta Secures $22.5M to Advance Clinical Trials in Cancer and Autoimmune Care
Details : The financing will hep the company to advance the clinical development of IDP-023, which is being evaluated in the early-stage clinical trial studies for the treatment of multiple myeloma.
Product Name : IDP-023
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 17, 2024
Lead Product(s) : IDP-023,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $22.5 million
Deal Type : Financing
Lead Product(s) : IDP-023,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indapta Treats First Patients with IDP-023 Allogeneic NK Cell Therapy for Cancer
Details : IDP-023 is a natural killer (NK) cell therapy which is currently being investigated in phase 1/2 clinical studies for the treatment of multiple myeloma and Non-Hodgkin’s lymphoma.
Product Name : IDP-023
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 01, 2024
Lead Product(s) : IDP-023,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indapta Announces Clinical Study Collaboration with Sanofi on Multiple Myeloma Program
Details : The collaboration will help Indapta to amend its ongoing phase 1 study of IDP-023, to add a cohort of IDP-023 in combination with Sarclisa for patients with relapsed/refractory multiple myeloma.
Product Name : IDP-023
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 12, 2024
Indapta & Sanofi Collaborate on Clinical Study for Multiple Myeloma Program
Details : #N/A
Product Name : IDP-023
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 12, 2024
Lead Product(s) : IDP-023,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : CPRIT
Deal Size : $4.5 million
Deal Type : Funding
Indapta Therapeutics Awarded $4.5 Million by CPRIT for Allogenic Cell Therapy
Details : The grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.
Product Name : IDP-023
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 21, 2024
Lead Product(s) : IDP-023,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : CPRIT
Deal Size : $4.5 million
Deal Type : Funding
Lead Product(s) : IDP-023,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indapta Receives FDA Fast Track Designation for IDP-023 in Non-Hodgkin’s Lymphoma
Details : IDP-023 is an allogeneic G-NK cell therapy, which is being evaluated for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.
Product Name : IDP-023
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : IDP-023,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDP-023,Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Leaps by Bayer
Deal Size : $60.0 million
Deal Type : Series A Financing
Details : The financing will be used for the first-in-human phase 1 trial of DP-023, an Allogeneic Natural Killer (NK) Cell Therapy in patients with multiple myeloma and lymphoma.
Product Name : IDP-023
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 17, 2023
Lead Product(s) : IDP-023,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Leaps by Bayer
Deal Size : $60.0 million
Deal Type : Series A Financing
Lead Product(s) : G-NK Cell
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : RA Capital Management
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : The company will use the proceeds of the financing to grow the team and continue to advance its universal, allogeneic NK cell platform toward an Investigational New Drug Application (IND) and clinical trials.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 02, 2022
Lead Product(s) : G-NK Cell
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : RA Capital Management
Deal Size : $50.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Multiple Myeloma Research Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Indapta Therapeutics is developing a universal, allogeneic G-NK cell therapy designed to substantially improve the cytotoxicity of monoclonal antibody therapy in multiple cancers.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 28, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Multiple Myeloma Research Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indapta Therapeutics Provides Updates on Its G-NK cell Therapy Program
Details : Company presented data from its G-NK cell therapy program in a poster presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in June.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 07, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable